ARCHIVES

Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable

This article is from The Cancer Letter archive.

Vol. 26 No. 1 | January 31, 2003

Download PDF Visit The Full Archive

Related Articles

Trial Links Potential Biomarkers To Drugs For Lung Cancer, To Help Target Therapies

April 30, 2010

Anonymous $100 Million Gift Moves OHSU Within $82 Million Of Reaching $1 Billion Goal

August 1, 2014

Clinical Trials Approved Last Month By NCI’s CTEP

May 31, 2002

FDA Grants Six-Month Priority Review To Nolvadex For DCIS Adjuvant Treatment.

March 31, 2000

NCI Moratorium On New OIG Applications; P01 Funding Steadily Drops

May 1, 1992

International Research Data Bank Up And Operating Through NLM Systems

September 20, 1974